GlaxoSmithKline PLC — Foreign Filer Report 2021

Feb 19, 2021

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2021

Commission File Number 001-15170

GlaxoSmithKline plc

(Translation of registrant's name into English)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

GlaxoSmithKline plc (the ' Company ')

Transaction notification

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Ms V Whyte | |
| --- | --- | --- | --- |
| b) | Position/status | Company Secretary | |
| c) | Initial
notification/ amendment | Initial Notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description of the financial
instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature of the transaction | Transfer of 10,726 Ordinary Shares between accounts for nil
consideration. | |
| c) | Price(s) and
volume(s) | Price(s) | Volume(s) |
| | | £0.00 | 10,726 |
| d) | Aggregated information | N/A (single transaction) | |
| | Aggregated volume Price | | |
| e) | Date
of the transaction | 2021-02-16 | |
| f) | Place of the
transaction | N/A | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Ms V Whyte | |
| --- | --- | --- | --- |
| b) | Position/status | Company Secretary | |
| c) | Initial
notification/ amendment | Initial Notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description of the financial
instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature of the transaction | Transfer of 10,870 Ordinary Shares to spouse for nil
consideration. | |
| c) | Price(s) and
volume(s) | Price(s) | Volume(s) |
| | | £0.00 | 10,870 |
| d) | Aggregated information | N/A (single transaction) | |
| | Aggregated volume Price | | |
| e) | Date
of the transaction | 2021-02-18 | |
| f) | Place of the
transaction | N/A | |

| a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr I Whyte | |
| --- | --- | --- | --- |
| b) | Position/status | PCA of Ms V Whyte (Company Secretary) | |
| c) | Initial
notification/ amendment | Initial Notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature of the transaction | Receipt of 10,870 Ordinary Shares from spouse for nil
consideration. | |
| c) | Price(s) and
volume(s) | Price(s) | Volume(s) |
| | | £0.00 | 10,870 |
| d) | Aggregated information | N/A (single transaction) | |
| | Aggregated volume Price | | |
| e) | Date
of the transaction | 2021-02-18 | |
| f) | Place of the
transaction | N/A | |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

(Registrant)
Date: February
19, 2021
By:/s/ VICTORIA
WHYTE --------------------------
Victoria Whyte
Authorised
Signatory for and on
behalf
of GlaxoSmithKline plc

page break